Plain-English translation of NCT05918523 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a follow-up study for people who participated in earlier trials of , an experimental treatment for chronic kidney disease. Researchers want to track how participants are doing long-term—up to five years after receiving the treatment—to understand whether the therapy continues to be safe and effective over time.
When new medical treatments are first tested, researchers need to follow patients for years afterward to see if the benefits last and if any side effects emerge over time. This study helps doctors understand the long-term impact of this cell-based kidney therapy.
You likely qualify if…
You likely don't qualify if…
Over the next five years, you'll have regular check-ins with the research team—some visits will be in-person at a clinic, and others will be phone calls, alternating back and forth. During these visits, the team will ask about your health, may do blood tests or other routine kidney function checks, and monitor how you're doing overall. There's no new treatment involved; this study is simply tracking your health to see how the medication you received earlier continues to affect your kidneys.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Enrollment target
~80 participants
Started
December 2023
Primary completion
January 2028
Age range
30 Years – 80 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Beth Hilburger
Prokidney
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.